<DOC>
	<DOC>NCT01652339</DOC>
	<brief_summary>To assess the pharmacokinetic characteristics of Lodivixx tab.5/160mg in healthy male subjects - PK parameter evaluation - Safety profile evaluation</brief_summary>
	<brief_title>Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Years 2045 Body weight ≥ 50kg and 18 ≤ BMI ≤ 29kg/m2 volunteer Subject with serious active cardiovascular, respiratory, hepatologic, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease Subject with symptoms of acute disease within 28days prior to study medication dosing Subject with known for history which affect on the absorption, distribution, metabolism or excretion of drug Subject with clinically significant active chronic disease Subject with any of the following conditions in laboratory test i. AST(sGOT) or ALT(sGPT) &gt; Upper normal limit × 1.5 ii. Total bilirubin &gt; Upper normal limit × 1.5 iii. renal failure with Creatinine clearance &lt; 50mL/min Clinically significant hypotension when screening period (SBP &lt; 100mmHg, DBP &lt; 60mmHg) Positive test results for HBs Ab, HCV Ab, Syphilis regain test Use of any prescription medication within 14 days prior to study medication dosing Use of any medication such as overthecounter medication including oriental medication within 7 days prior to study medication dosing Subject with clinically significant allergic disease (except for mild allergic rhinitis and mild allergic dermatitis that are not needed to administer drug) Subject with known for hypersensitivity reaction to Samlodipine, amlodipine and valsartan and dihydropyridine derivatives Subject who is not able to taking the institutional standard meal Subjects with whole blood donation within 60days, component blood donation within 20days Subjects receiving blood transfusion within 30days prior to study medication dosing Participation in any clinical investigation within 60days prior to study medication dosing Continued excessive use of caffeine (caffeine &gt; five cups/day), alcohol(alcohol&gt;30g/day) and severe heavy smoker (cigarette &gt; 10 cigarettes per day) Subject who has been taken meal which affect on the absorption, distribution, metabolism, excretion of drug, especially grapefruit juice Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within 28days prior to study medication dosing Continued serum potassium concentration abnormal status (on baseline visit, &lt; 3.5mEq/L or &gt; 5.5mEq/L) Subjects with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as nonresponding to request or instruction by investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>